The US-headquartered company, which recently became an integrated contract development and manufacturing organisation (CDMO) by acquiring Avista, continued a series of investments at its Swedish site.
The three-story building includes process technology, QC and analytical development laboratories and is expected to house the R&D and production teams.
This investment of $5m (€4.42m), which was announced in 2018, is expected to employ computer modeling to optimize reactor set ups and plant conditions to improve technology transfer between the teams.
According to the company, the laboratory also includes high pressure reaction vessels and crystallization equipment for drug substance manufacturing, extending the capabilities for handling in-process and raw material analysis.
The equipment is also expected to expand the temperature range at which reactions can be carried out, with vessels capable of managing conditions from cryogenic levels to nearly 200°C.
“The new technical laboratory will act as a hub for the company’s engineers, operators and chemists to ensure smooth scale up and handover of processes from development sites across our global network,” said Bjarne Sandberg, managing director at Cambrex.
In order to support the site’s growth, which has included the expansion of large scale manufacturing capacity, Cambrex also opened a $6m, 3,000-square-meter logistics center.
The warehouse is current good manufacturing practice (cGMP)-compliant, with integral temperature monitoring and control, and has the capacity for 4,500 pallets.
